Influx Healthtech Board of Directors

Get the latest insights into the leadership at Influx Healthtech. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Munir Abdul Ganee Chandniwala Chairman & Managing Director
Mrs. Shirin Munir Ahmed Chandniwala Whole Time Director
Mr. Abdul Ganee Abdul Rasul Chandniwala Non Executive Director
Mr. Ashok Kumar Jain Independent Director
Mr. Vipul Balubhai Patel Independent Director

Influx Healthtech Share price

INFLUX

192.25

0.15 (0.08%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:22 IST
BUYSELL
Today's High

202.65

Today's Low

190.00

52 Week Low

120.00

52 Week High

202.65

The current prices are delayed, login to your account for live prices

Influx Healthtech FAQs

The board at Influx Healthtech consists of experienced professionals, including Mr. Munir Abdul Ganee Chandniwala , Mrs. Shirin Munir Ahmed Chandniwala , and others, overseeing the company’s strategic and corporate governance.

Directors at Influx Healthtech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Munir Abdul Ganee Chandniwala is the current chairman at Influx Healthtech.

Executive directors at Influx Healthtech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Influx Healthtech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Influx Healthtech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.